2012
DOI: 10.1159/000339168
|View full text |Cite
|
Sign up to set email alerts
|

Genistein Attenuates Advanced Glycation End Product-Induced Expression of Fibronectin and Connective Tissue Growth Factor

Abstract: <b><i>Objective:</i></b> To investigate the effect of advanced glycation end products (AGEs) on the expression of connective tissue growth factor (CTGF) and fibronectin (FN) in human peritoneal mesothelial cells (HPMC). To observe the effect of genistein (Gen) on the expression of CTGF and FN in HPMC induced by AGEs. <b><i>Methods:</i></b> First, HPMC were stimulated with different concentrations of AGEs (0, 200, 600 and 1,000 mg/l) for 48 h; the expression of FN… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
3
0

Year Published

2013
2013
2024
2024

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 7 publications
(3 citation statements)
references
References 85 publications
0
3
0
Order By: Relevance
“…This promotes mesothelial cell production of fibronectin via the induction of the ERK1/2 and MAPK pathways thereby contributing to peritoneal injury and inflammation ( Kiribayashi et al, 2005 ). The increased production of fibronectin by mesothelial cells can also be induced by the presence of advanced glycation end products (AGEs; Tong et al, 2012 ).…”
Section: Mesothelial Cell Functionsmentioning
confidence: 99%
See 1 more Smart Citation
“…This promotes mesothelial cell production of fibronectin via the induction of the ERK1/2 and MAPK pathways thereby contributing to peritoneal injury and inflammation ( Kiribayashi et al, 2005 ). The increased production of fibronectin by mesothelial cells can also be induced by the presence of advanced glycation end products (AGEs; Tong et al, 2012 ).…”
Section: Mesothelial Cell Functionsmentioning
confidence: 99%
“…Other cell sources that may be used for mesothelial repair include bone marrow derived cells ( Sekiguchi et al, 2012 ), adipose-derived stem cells ( Kim et al, 2014 ), and mesenchymal stem cells ( Wang et al, 2012 ; Ueno et al, 2013 ). Alternative therapeutic strategies being investigated to reduce mesothelial cell-mediated inflammation and prevent peritoneal fibrosis include targeting TGFβ1-mediated mechanisms ( Hung et al, 2001 , 2003 ; Yung et al, 2001 ; Margetts et al, 2002a ; Fang et al, 2006 ; Tomino, 2012 ; Jang et al, 2013 ), reducing mesothelial cell production of fibronectin ( Tong et al, 2012 ; Zhang et al, 2014 ) developing a more bio compatible PD solution ( Bajo et al, 2000 ; Le Poole et al, 2005 ), altering PD daily dwelling time ( Lee et al, 2014 ), and stimulating fibrinolytic agents ( Haslinger et al, 2003 ).…”
Section: The Mesothelial Cell In Fibrotic Disordersmentioning
confidence: 99%
“…The production level of ECM is increased by IL-1β, TNF-α, EGF, and TGF-β [65][66][67][68][69][70][71][72][73][74][75]. The renin-angiotensin system or AGEs also stimulates ECM production [76,77]. MC provides a protective and non-adhesive surface for intracoelomic organs and tissues.…”
Section: Synthesis Of Extracellular Matrix (Ecm)mentioning
confidence: 99%